~~<i id='C727BB6806'><strike id='C727BB6806'><tt id='C727BB6806'><pre id='C727BB6806'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：fashion 2025-09-27 16:49:28 - browse：8

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

knowledge

focus

knowledge

leisure time

focus

7:06FormerPresidentDonaldTrumpspeaksduringthe56thannualSilverElephantGalainColumbia,S.C.,Aug.5,2023.

WSS

Doctors are clamoring for more clarity on Paxlovid prescribing

Flash flood warnings continue for parts of Missouri, Illinois

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Paxlovid rebound happens. Why and to whom are still a mystery

Spinal cord stimulation reduces pain in amputees, study finds

Restaurant meals are packed with calories, and we still keep eating them

focus

comprehensive

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Google's generative AI to analyze medical images — and talk to docs

Wildfire smoke exposes gaps in outdoor worker protections

Americans' trust in science, scientist continues decline: Report

How to save PrEP access — and even expand it

Why sickle cell disease is getting the first CRISPR treatment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pfizer plans to depart BIO

DIEP, the 'gold standard' of breast reconstruction, is under threat

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

focus

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Chemotherapy shortages won’t get better under Biden’s latest plan

CMS should re

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Doctors push to include dialysis machines in emergency stockpile

Roche to buy Carmot Therapeutics, developer of obesity drugs

knowledge

leisure time

focus

focus